Retrospective studies comparing outcomes using related haplo donors vs matched unrelated donors
| Reference . | Donor . | N . | Disease . | Conditioning for haplo . | GVHD prophylaxis . | Overall survival (%) . | Disease-free survival (%) . | Nonrelapse mortality (%) . | Acute GVHD (%) . | Chronic GVHD (%) . | Relapse (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Burroughs et al14 (multicenter) | MRD | 38 | Hodgkin | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | CNI/MMF | 53 | 23 | 21 | 16 | 50 | 56 |
| (m)MUD | 24 | Lymphoma | CNI/MMF | 58 | 29 | 8 | 8 | 63 | 63 | ||
| Haplo | 28 | PTCY/FK/MMF | 58 (2 y) | 51 (2 y) | 9 (2 y) | 11 (III/IV) | 35 (extensive, 2 y) | 40 (2 y) | |||
| Bashey et al15 (single center) | MRD | 117 | Mixed malignancy | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | NR | 76 | 53 | 13 | 8 | 54 | 34 |
| (m)MUD | 101 | MA | NR | 67 | 52 | 16 | 11 | 54 | 34 | ||
| Haplo | 53 | Fludarabine, busulfan, cyclophosphamide | PTCY/FK/MMF | 64 (2 y) | 60 (2 y) | 7 (2 y) | 11 (III/IV, 6 mo) | 38 (extensive) | 33 (2 y) | ||
| Di Stasi et al8 (single center) | MRD | 87 | AML/MDS | NMA (fludarabine, melphalan, thiotepa) | FK/MTX | NR | 36 | 20 | 11 | 31 | NR |
| (m)MUD | 108 | FK/MTX +ATG | NR | 27 | 35 | 6 | 21 | NR | |||
| Haplo | 32 | PTCY/FK/MMF | NR | 30 (3 y) | 24 (1 y) | 0 (III/IV) | 11 (extensive, 3 y) | NR | |||
| Raiola et al4 (single center) | MRD | 176 | Mixed malignancy | Multiple different regimens used MA in 77% | CsA/MTX | 45 | 32 | 24 | 7 | 29 | 40 |
| MUD | 43 | CsA/MTX + ATG | 43 | 36 | 33 | 3 | 22 | 23 | |||
| (m)MUD | 43 | CsA/MTX + ATG | 40 | 34 | 35 | 9 | 19 | 30 | |||
| Haplo | 92 | PTCY/CsA/MMF | 52 | 43 | 18 | 4 | 15 | 35 | |||
| UCB | 103 | CsA/MMF + ATG | 34 (4 y) | 33 (4 y) | 35 (1000 d) | 1 (III/IV) | 23 | 30 | |||
| Solomon et al25 (single center) | (m)MUD | 48 | Mixed malignancy | MA (Cy-TBI fludarabine) | Tacro/MTX | 78 | 73 | 23 | 63 | 58 | 23 |
| Haplo | 30 | PTCY/tacro/MMF | 71 (2 y) | 64 (2 y) | 3 (2 y) | 43 (all grade) | 22 (moderate/severe) | 24 (2 y) | |||
| Kanate et al9 (registry study) | MUD | 491 | Lymphoma | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | CNI | 62 | 49 | 22 | 60 | 62 | 28 |
| MUD | 241 | CNI +ATG | 50 | 47 | 26 | 56 | 37 | 36 | |||
| Haplo | 185 | PTCY/CNI/MMF | 60 (3 y) | 38 (3 y) | 17 (3 y) | 52 (all grade, 6 mo) | 15 (all grade, 2 y) | 36 (3 y) | |||
| Ciurea et al7 (registry study) | MUD | 1982 | AML | Multiple different regimens used MA in 54% | CNI + MMF/MTX | 44(RIC)50(MA) | NR | 23 (RIC), 20 (MA) | 11 (RIC), 13 (MA) | 52 (RIC), 53 (MA) | 42 (RIC), 39 (MA) |
| Haplo | 192 | PTCY/CNI/MMF | 46(RIC) 45(MA) (3 y) | NR | 9 (RIC), 14 (MA) (3 y) | 2 (RIC), 7 (MA) (III-IV, day 90) | 34 (RIC), 30 (MA) (3 y) | 58 (RIC), 44 (MA) (3 y) | |||
| Blaise et al6 (single center) | MRD | 47 | Mixed malignancy | Multiple different regimens used NMA in 68% | CsA + ATG | 78 | 64 | 11 | 13 | 16 | 25 |
| (m)MUD | 63 | RIC in 32% | CsA + ATG (±MMF) | 51 | 38 | 34 | 25 | 14 | 31 | ||
| Haplo | 31 | PTCY/CsA/MMF | 70 (2 y) | 67 (2 y) | 10 (2 y) | 10 (III/IV) | 0 (severe, 2 y) | 23 (2 y) | |||
| Bashey et al5 (single center) | MRD | 181 | Mixed malignancy | Multiple different regimens used | Tacro/MTX ± ATG | 72 | 56 | 14 | 28 | 44 | 30 |
| MUD | 178 | Tacro/MTX ± alemtuzumab | 59 | 50 | 16 | 48 | 47 | 34 | |||
| Haplo | 116 | MA in 40% | PTCY | 57 (2 y) | 54 (2 y) | 17 (2 y) | 41 (2 y) | 31 (moderate/severe, 2 y) | 29 (2 y) | ||
| Baker et al10 (single center) | (m)MUD | 59 | Mixed malignancy | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | Tacro/MTX or MMF + ATG | 403 | 293 | 29 | 8 | 18 | 46 |
| Haplo | 54 | PTCY/tacro/MMF | 465 (median days) | 245 (median days) | 28 (2 y) | 13 (III-IV, day 180) | 24 (moderate/severe, 2 y) | 44 (2 y) |
| Reference . | Donor . | N . | Disease . | Conditioning for haplo . | GVHD prophylaxis . | Overall survival (%) . | Disease-free survival (%) . | Nonrelapse mortality (%) . | Acute GVHD (%) . | Chronic GVHD (%) . | Relapse (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Burroughs et al14 (multicenter) | MRD | 38 | Hodgkin | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | CNI/MMF | 53 | 23 | 21 | 16 | 50 | 56 |
| (m)MUD | 24 | Lymphoma | CNI/MMF | 58 | 29 | 8 | 8 | 63 | 63 | ||
| Haplo | 28 | PTCY/FK/MMF | 58 (2 y) | 51 (2 y) | 9 (2 y) | 11 (III/IV) | 35 (extensive, 2 y) | 40 (2 y) | |||
| Bashey et al15 (single center) | MRD | 117 | Mixed malignancy | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | NR | 76 | 53 | 13 | 8 | 54 | 34 |
| (m)MUD | 101 | MA | NR | 67 | 52 | 16 | 11 | 54 | 34 | ||
| Haplo | 53 | Fludarabine, busulfan, cyclophosphamide | PTCY/FK/MMF | 64 (2 y) | 60 (2 y) | 7 (2 y) | 11 (III/IV, 6 mo) | 38 (extensive) | 33 (2 y) | ||
| Di Stasi et al8 (single center) | MRD | 87 | AML/MDS | NMA (fludarabine, melphalan, thiotepa) | FK/MTX | NR | 36 | 20 | 11 | 31 | NR |
| (m)MUD | 108 | FK/MTX +ATG | NR | 27 | 35 | 6 | 21 | NR | |||
| Haplo | 32 | PTCY/FK/MMF | NR | 30 (3 y) | 24 (1 y) | 0 (III/IV) | 11 (extensive, 3 y) | NR | |||
| Raiola et al4 (single center) | MRD | 176 | Mixed malignancy | Multiple different regimens used MA in 77% | CsA/MTX | 45 | 32 | 24 | 7 | 29 | 40 |
| MUD | 43 | CsA/MTX + ATG | 43 | 36 | 33 | 3 | 22 | 23 | |||
| (m)MUD | 43 | CsA/MTX + ATG | 40 | 34 | 35 | 9 | 19 | 30 | |||
| Haplo | 92 | PTCY/CsA/MMF | 52 | 43 | 18 | 4 | 15 | 35 | |||
| UCB | 103 | CsA/MMF + ATG | 34 (4 y) | 33 (4 y) | 35 (1000 d) | 1 (III/IV) | 23 | 30 | |||
| Solomon et al25 (single center) | (m)MUD | 48 | Mixed malignancy | MA (Cy-TBI fludarabine) | Tacro/MTX | 78 | 73 | 23 | 63 | 58 | 23 |
| Haplo | 30 | PTCY/tacro/MMF | 71 (2 y) | 64 (2 y) | 3 (2 y) | 43 (all grade) | 22 (moderate/severe) | 24 (2 y) | |||
| Kanate et al9 (registry study) | MUD | 491 | Lymphoma | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | CNI | 62 | 49 | 22 | 60 | 62 | 28 |
| MUD | 241 | CNI +ATG | 50 | 47 | 26 | 56 | 37 | 36 | |||
| Haplo | 185 | PTCY/CNI/MMF | 60 (3 y) | 38 (3 y) | 17 (3 y) | 52 (all grade, 6 mo) | 15 (all grade, 2 y) | 36 (3 y) | |||
| Ciurea et al7 (registry study) | MUD | 1982 | AML | Multiple different regimens used MA in 54% | CNI + MMF/MTX | 44(RIC)50(MA) | NR | 23 (RIC), 20 (MA) | 11 (RIC), 13 (MA) | 52 (RIC), 53 (MA) | 42 (RIC), 39 (MA) |
| Haplo | 192 | PTCY/CNI/MMF | 46(RIC) 45(MA) (3 y) | NR | 9 (RIC), 14 (MA) (3 y) | 2 (RIC), 7 (MA) (III-IV, day 90) | 34 (RIC), 30 (MA) (3 y) | 58 (RIC), 44 (MA) (3 y) | |||
| Blaise et al6 (single center) | MRD | 47 | Mixed malignancy | Multiple different regimens used NMA in 68% | CsA + ATG | 78 | 64 | 11 | 13 | 16 | 25 |
| (m)MUD | 63 | RIC in 32% | CsA + ATG (±MMF) | 51 | 38 | 34 | 25 | 14 | 31 | ||
| Haplo | 31 | PTCY/CsA/MMF | 70 (2 y) | 67 (2 y) | 10 (2 y) | 10 (III/IV) | 0 (severe, 2 y) | 23 (2 y) | |||
| Bashey et al5 (single center) | MRD | 181 | Mixed malignancy | Multiple different regimens used | Tacro/MTX ± ATG | 72 | 56 | 14 | 28 | 44 | 30 |
| MUD | 178 | Tacro/MTX ± alemtuzumab | 59 | 50 | 16 | 48 | 47 | 34 | |||
| Haplo | 116 | MA in 40% | PTCY | 57 (2 y) | 54 (2 y) | 17 (2 y) | 41 (2 y) | 31 (moderate/severe, 2 y) | 29 (2 y) | ||
| Baker et al10 (single center) | (m)MUD | 59 | Mixed malignancy | NMA (fludarabine, 2-Gy TBI, cyclophosphamide) | Tacro/MTX or MMF + ATG | 403 | 293 | 29 | 8 | 18 | 46 |
| Haplo | 54 | PTCY/tacro/MMF | 465 (median days) | 245 (median days) | 28 (2 y) | 13 (III-IV, day 180) | 24 (moderate/severe, 2 y) | 44 (2 y) |
Bold indicates significant differences between haplo and matched UD.
AML, acute myeloid leukemia; ATG, anti–thymocyte globulin; CNI, calcineurin inhibitor; CsA, cyclosporine; FK, FK506 (tacrolimus); GVHD, graft-versus-host disease; MA, myeloablative conditioning; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX, methotrexate; MRD, matched related donor; (m)MUD, (mis)matched unrelated donor; NR, not reported; NMA, nonmyeloablative conditioning; PTCY, posttransplant cyclophosphamide; RIC, reduced-intensity conditioning; tacro, tacrolimus TBI, total body irradiation; UCB, umbilical cord blood.